These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23959464)

  • 21. Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways.
    Yang L; Hu Y; Zhou G; Chen Q; Song Z
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regorafenib delays the proliferation of hepatocellular carcinoma by inducing autophagy.
    Han R; Li S
    Pharmazie; 2018 Apr; 73(4):218-222. PubMed ID: 29609689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
    Ha TY; Hwang S; Hong HN; Choi YI; Yoon SY; Won YJ; Song GW; Kim N; Tak E; Ryoo BY
    Anticancer Res; 2015 Apr; 35(4):1985-95. PubMed ID: 25862851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
    Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
    J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells.
    Refolo MG; Lippolis C; Carella N; Cavallini A; Messa C; D'Alessandro R
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Akebia trifoliata (Thunb.) Koidz Seed Extract inhibits human hepatocellular carcinoma cell migration and invasion in vitro.
    Lu WL; Yang T; Song QJ; Fang ZQ; Pan ZQ; Liang C; Jia DW; Peng PK
    J Ethnopharmacol; 2019 Apr; 234():204-215. PubMed ID: 30528882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-invasion and anti-metastasis effects of Valjatrate E via reduction of matrix metalloproteinases expression and suppression of MAPK/ERK signaling pathway.
    Sun Y; Lan M; Chen X; Dai Y; Zhao X; Wang L; Zhao T; Li Y; Zhu J; Zhang X; Jiang H; Wu X; Chen C; Zhang T; Yan Z
    Biomed Pharmacother; 2018 Aug; 104():817-824. PubMed ID: 29703569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
    Naruto K; Kawaoka T; Amioka K; Ogawa Y; Chihiro K; Yoshikawa Y; Ando Y; Suehiro Y; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Murakami E; Nakahara T; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Takaki S; Mori N; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Kohno H; Kohno H; Moriya T; Naeshiro N; Azakami T; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):491-498. PubMed ID: 34000725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression.
    Wang B; Wang F; Ding A; Zhao H; Bu X
    Clin Transl Oncol; 2020 Sep; 22(9):1491-1498. PubMed ID: 31965535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sauchinone exerts anticancer effects by targeting AMPK signaling in hepatocellular carcinoma cells.
    Kim YW; Jang EJ; Kim CH; Lee JH
    Chem Biol Interact; 2017 Jan; 261():108-117. PubMed ID: 27871897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H; Ong R; Zopf D
    J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.